Lung cancer survival rates are up thanks to immunotherapy, other ... - NPR
WEBApr 12, 2024 · Lung cancer remains the most lethal form of the disease, killing about 135,000 Americans a year – more than breast, prostate and colon cancer combined – which is why many people still think of...
Osimertinib Improves Survival in Lung Cancer - NCI
WEBJul 5, 2023 · Improved overall survival with osimertinib. The initial results from ADAURA, published in October 2020, offered signs of possible survival improvements with adjuvant osimertinib. This treatment, they showed, dramatically improved how long people lived without any evidence of their cancer returning.
Targeted Drug Stops Lung Cancer Growth for Five Years in Over …
WEBJun 13, 2024 · A study shows that a targeted therapy drug stops the spread of lung cancer for 5 years or more. The drug, lorlatinib (Lobrena), also stops new cancer growth in the brain. These benefits were seen in 3 out of every 5 people with advanced non-small cell lung cancer (NSCLC) with an ALK gene mutation.
After Four Decades, a Breakthrough for Lung Cancer
WEBLearn about just some of our achievements in this Annual Report. When Karen Milich stopped responding to lung cancer treatments, she enrolled in an MSK-led clinical trial testing a drug that targets the KRAS mutation. The drug, sotorasib, was a breakthrough, 40 years in the making.
Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI
WEBFeb 16, 2024 · Treatment with repotrectinib can shrink tumors in people with advanced lung cancer whose tumors have ROS1 fusions. FDA approved the drug in 2023 as an initial or second-line treatment for ROS1-positive NSCLC.
US lung cancer survival rates rise, but it’s still the leading ... - CNN
WEBNov 14, 2023 · CNN — Over the past five years, the five-year survival rate for lung cancer in the US has increased a significant 22%, according to a new report from the American Lung Association. But the...
Adjuvant Immunotherapy Approved for Lung Cancer - NCI
WEBOct 26, 2021 · FDA has approved the immunotherapy atezolizumab (Tecentriq) as an additional, or adjuvant, treatment for some patients with non-small cell lung cancer (NSCLC). With the approval, atezolizumab becomes the first checkpoint inhibitor approved as an adjuvant treatment for lung cancer.
Lung cancer - Latest research and news - Nature
WEB4 days ago · Latest Research and Reviews. Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography.
FDA Approves First Targeted Therapy for Lung Cancer Mutation …
WEBMay 28, 2021. Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific...
Lung cancer deaths cut in half with AstraZeneca pill, large ... - NBC News
WEBJun 5, 2023 · By Aria Bendix. A once-daily pill from drugmaker AstraZeneca cut deaths in half among a subset of early-stage lung cancer patients who had undergone surgery, according to new clinical trial...